Meeting of the Advisory Committee on Blood Safety and Availability, 16871-16872 [E9-8398]
Download as PDF
<![CDATA[
Federal Register / Vol. 74, No. 69 / Monday, April 13, 2009 / Notices
President) 701 East Byrd Street,
Richmond, Virginia 23261–4528:
1. MidCap Financial Holdings, LLC,
and MidCap Bank Holdings, Inc., both
of Bethesda, Maryland, to become bank
holding companies by acquiring 100
percent of the voting shares of ISN
Bank, Cherry Hill, New Jersey.
In connection with this application,
MidCap Financial Holdings, LLC,
Bethesda, Maryland, also has applied to
engage in extending credit and servicing
loans through MidCap Financial
Intermediate Holdings, LLC; MidCap
Financial, LLC; and MidCap Funding I,
LLC, all of Bethesda, Maryland,
pursuant to section 225.28(b)(1) of
Regulation Y.
Board of Governors of the Federal Reserve
System, April 8, 2009.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E9–8327 Filed 4–10–09; 8:45 am]
BILLING CODE 6210–01–S
GENERAL SERVICES
ADMINISTRATION
Multiple Award Schedule Advisory
Panel; Notification of Public Advisory
Panel Meetings
AGENCY: U.S. General Services
Administration (GSA).
ACTION: Notice.
SUMMARY: The U.S. General Services
Administration (GSA) Multiple Award
Schedule Advisory Panel (MAS Panel),
a Federal Advisory Committee, will
hold a public meeting on Friday, May 1,
2009. GSA utilizes the MAS program to
establish long-term Governmentwide
contracts with responsible firms to
provide Federal, State, and local
government customers with access to a
wide variety of commercial supplies
(products) and services.
The MAS Panel was established to
develop advice and recommendations
on MAS program pricing policies,
provisions, and procedures in the
context of current commercial pricing
practices. The Panel is developing
recommendations for MAS program
pricing provisions for the acquisition of
(1) professional services; (2) products;
(3) total solutions which consist of
professional services and products; and
(4) non professional services. In
developing the recommendations, the
Panel will, at a minimum, address these
5 questions for each of the 4 types of
acquisitions envisioned above: (1)
Where does competition take place?; (2)
If competition takes place primarily at
the task/delivery order level, does a fair
and reasonable price determination at
VerDate Nov<24>2008
18:51 Apr 10, 2009
Jkt 217001
the MAS contract level really matter?;
(3) If the Panel consensus is that
competition is at the task order level,
are the methods that GSA uses to
determine fair and reasonable prices
and maintain the price/discount
relationship with the basis of award
customer(s) adequate?; (4) If the current
policy is not adequate, what are the
recommendations to improve the
policy/guidance; and (5) If fair and
reasonable price determination at the
MAS contract level is not beneficial and
the fair and reasonable price
determination is to be determined only
at the task/delivery order level, then
what is the GSA role?
The meeting will be held at U.S.
General Services Administration,
Federal Acquisition Service, 2200
Crystal Drive, Room L1301, Arlington,
VA 22202. The location is within
walking distance of the Crystal City
metro stop. The start time for each
meeting is 9 a.m., and each meeting will
adjourn no later than 5 p.m.
FOR FURTHER INFORMATION CONTACT:
Information on the Panel meetings,
agendas, and other information can be
obtained at www.gsa.gov/
masadvisorypanel or you may contact
Ms. Pat Brooks, Designated Federal
Officer, Multiple Award Schedule
Advisory Panel, U.S. General Services
Administration, 2011 Crystal Drive,
Suite 911, Arlington, VA 22205;
telephone (703) 605–3406, Fax (703)
605–3454; or via email at
mas.advisorypanel@gsa.gov.
AVAILABILITY OF MATERIALS: All
meeting materials, including meeting
agendas, handouts, public comments,
and meeting minutes will be posted on
the MAS Panel website at www.gsa.gov/
masadvisorypanel or www.gsa.gov/
masap.
MEETING ACCESS: Individuals
requiring special accommodations at
any of these meetings should contact
Ms. Brooks at least ten (10) business
days prior to the meeting date so that
appropriate arrangements can be made.
Dated: April 7, 2009.
Rodney P. Lantier,
Acting Deputy Chief Acquisition Officer and
Senior Procurement Executive, Office of the
Chief Acquisition Officer, General Services
Administration.
[FR Doc. E9–8320 Filed 4–10–09; 8:45 am]
BILLING CODE 6820–EP–S
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
16871
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood Safety and Availability
AGENCY: Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood Safety
and Availability (ACBSA) will hold a
meeting. The meeting will be open to
the public.
DATES: The meeting will take place
Thursday, April 30 and Friday, May 1,
2009 from 9 a.m. to 5 p.m.
ADDRESSES: The Universities at Shady
Grove, 9630 Gudelsky Drive, Rockville,
MD 20850, Phone: 301–738–6000.
FOR FURTHER INFORMATION CONTACT: Jerry
A. Holmberg, PhD, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 250, Rockville, MD
20852, (240) 453–8803, FAX (240) 453–
8456, e-mail ACBSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Advisory Committee on Blood Safety
and Availability provides advice to the
Secretary and the Assistant Secretary for
Health on a range of policy issues that
impact (1) definition of public health
parameters around safety and
availability of the blood supply and
blood products, (2) broad public health,
ethical and legal issues related to
transfusion and transplantation safety,
and (3) the implications for safety and
the availability of various economic
factors affecting product cost and
supply. In keeping with its established
mission, the ACBSA has been asked to
explore processes and parameters which
should be used in the decision-making
process for transfusion and
transplantation safety policy. At the
April 30 to May 1, 2009 meeting, the
Committee will be asked to comment on
evidenced-based, zero-risk, cost, benefit
and comparative effectiveness, societal
position or mandate, ethical, and
stakeholders concerns.
The public will have opportunity to
present their views to the Committee on
both meeting days. A public comment
session has been scheduled for April 30
and May 1, 2009. Comments will be
limited to five minutes per speaker and
must be pertinent to the discussion. Preregistration is required for participation
in the public comment session. Any
E:\FR\FM\13APN1.SGM
13APN1
16872
Federal Register / Vol. 74, No. 69 / Monday, April 13, 2009 / Notices
member of the public who would like to
participate in this session is encouraged
to contact the Executive Secretary at
his/her earliest convenience. It is
requested that those who wish to have
printed material distributed to the
Committee provide thirty (30) copies of
the document to be distributed to the
Executive Secretary, ACBSA, prior to
close of business April 27, 2009. If it is
not possible to provide 30 copies of the
material to be distributed, then
individuals are requested to provide at
a minimum one (1) copy of the
document(s) to be distributed prior to
the close of business April 27, 2009. It
also is requested that any member of the
public who wishes to provide comments
to the Committee utilizing electronic
data projection submit the necessary
material to the Executive Secretary prior
to close of business April 27, 2009.
Dated: April 8, 2009.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on
Blood Safety and Availability.
[FR Doc. E9–8398 Filed 4–10–09; 8:45 am]
BILLING CODE 4140–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Solicitation of Written Comments on
Draft National Vaccine Advisory
Committee Vaccine Safety Working
Group Recommendations to the
Immunization Safety Office
AGENCY: Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
SUMMARY: The National Vaccine
Program Office (NVPO) is soliciting
public comment on the National
Vaccine Advisory Committee (NVAC)
Vaccine Safety Working Group draft
Recommendations to the Centers for
Disease Control and Prevention’s
Immunization Safety Office (ISO).
DATES: Comments on the NVAC Vaccine
Safety Working Group draft report
should be received no later than 5 p.m.
on May 13, 2009.
ADDRESSES: Electronic responses are
preferred and may be addressed to
vaccinesafetyRFI@hhs.gov. Written
responses should be addressed to
National Vaccine Program Office, U.S.
Department of Health and Human
Services, 200 Independence Avenue,
SW., Room 715–H, Washington, DC
20201, Attention: Vaccine Safety RFI.
FOR FURTHER INFORMATION CONTACT: Ms.
Kirsten Vannice, National Vaccine
Program Office, Department of Health
and Human Services, Hubert H.
VerDate Nov<24>2008
18:51 Apr 10, 2009
Jkt 217001
Humphrey Building, 200 Independence
Avenue, SW., Room 443–H,
Washington, DC 20201; telephone (202)
690–5566; fax 202–260–1165; e-mail
vaccinesafetyRFI@hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Ensuring the optimal safety of
vaccines and immunizations is
important to everyone. The National
Vaccine Program Office (NVPO) is
located within the Office of Public
Health and Science, Office of the
Secretary, Department of Health and
Human Services (HHS), and has
responsibility for coordinating and
ensuring collaboration among the many
Federal agencies involved in vaccine
and immunization activities. NVPO also
has responsibility for managing and
providing support services for the
National Vaccine Advisory Committee
(NVAC). NVAC is a statutory Federal
advisory committee that was established
to provide advice and make
recommendations to the Director of the
National Vaccine Program on matters
related to the Program’s responsibilities.
The Assistant Secretary for Health
serves as Director of the National
Vaccine Program.
The Centers for Disease Control and
Prevention’s (CDC) Immunization Safety
Office (ISO) has significant
responsibility for monitoring and
studying the safety of vaccines after they
are licensed and used in the United
States (https://www.cdc.gov/
vaccinesafety). ISO has drafted a fiveyear scientific agenda that identifies
vaccine safety issues to consider for
scientific study, in addition to any new
questions that may arise. The draft ISO
Scientific Agenda can be found at:
https://www.cdc.gov/vaccinesafety/
00_pdf/draft_agenda_
recommendations_080404.pdf and the
addendum at https://www.cdc.gov/
vaccinesafety/00_pdf/
draft_recommendations_add_080410
.pdf.
Since not all questions and issues can
be addressed at once, setting priorities
is also important, and ISO has requested
a review of the draft Scientific Agenda
by the National Vaccine Advisory
Committee (NVAC) for the purpose of
identifying gaps and setting priorities.
The NVAC Vaccine Safety Working
Group has written a draft report of
recommendations on the content and
priorities of the draft ISO Scientific
Agenda. The draft report may be found
at https://www.hhs.gov/nvpo/nvac/
reports.html.
Through this request for information
(RFI) HHS is seeking comments from
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
everyone, including stakeholders and
the broad public, on the NVAC Vaccine
Safety Working Group draft report.
Comments received will be available for
public viewing on the NVAC Vaccine
Safety Working Group Web site (https://
www.hhs.gov/nvpo/nvac/
vaccinesafety.html).
II. Information Request
NVPO, on behalf of the NVAC
Vaccine Safety Working Group, requests
input on the draft Working Group report
(https://www.hhs.gov/nvpo/nvac/
reports.html). In addition to general
comments, NVPO is seeking input on
any additional gaps not addressed in the
ISO Scientific Agenda nor the NVAC
Vaccine Safety Working Group draft
report, and/or prioritization criteria and
its application to the ISO Scientific
Agenda.
Please limit comments to 6 pages.
III. Potential Responders
HHS invites input from a broad range
of individuals and organizations that
have interests in vaccines and vaccine
safety. Some examples of these
organizations include but are not
limited to the following:
—General public;
—Advocacy groups and public interest
organizations;
—State and local governments;
—State and local public health
departments;
—Vaccine manufacturing industry,
distributors and other businesses;
—Health care professional societies and
organizations.
When responding, please self-identify
with any of the above or other categories
(include all that apply) and your name.
All comments submitted will be made
publicly available. Anonymous
submissions will not have their
comments posted and will not be
considered.
The submission of written materials
in response to the RFI should not
exceed six pages, not including
appendices and supplemental
documents. Responders may submit
other forms of electronic materials to
demonstrate or exhibit concepts of their
written responses. Any information you
submit will be made public.
Consequently, do not send proprietary,
commercial, financial, business
confidential, trade secret, or personal
information that you do not wish to be
made public.
Public Access: Responses to this RFI
will be available to the public on the
NVAC Web site at https://www.hhs.gov/
nvpo/nvac/vaccinesafety.html. You may
access public comments received from
this RFI by going to the above Web site.
E:\FR\FM\13APN1.SGM
13APN1
]]>Agencies
[Federal Register Volume 74, Number 69 (Monday, April 13, 2009)]
[Notices]
[Pages 16871-16872]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-8398]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood Safety and
Availability
AGENCY: Department of Health and Human Services, Office of the
Secretary.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood Safety and Availability (ACBSA) will
hold a meeting. The meeting will be open to the public.
DATES: The meeting will take place Thursday, April 30 and Friday, May
1, 2009 from 9 a.m. to 5 p.m.
ADDRESSES: The Universities at Shady Grove, 9630 Gudelsky Drive,
Rockville, MD 20850, Phone: 301-738-6000.
FOR FURTHER INFORMATION CONTACT: Jerry A. Holmberg, PhD, Executive
Secretary, Advisory Committee on Blood Safety and Availability, Office
of Public Health and Science, Department of Health and Human Services,
1101 Wootton Parkway, Suite 250, Rockville, MD 20852, (240) 453-8803,
FAX (240) 453-8456, e-mail ACBSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The Advisory Committee on Blood Safety and
Availability provides advice to the Secretary and the Assistant
Secretary for Health on a range of policy issues that impact (1)
definition of public health parameters around safety and availability
of the blood supply and blood products, (2) broad public health,
ethical and legal issues related to transfusion and transplantation
safety, and (3) the implications for safety and the availability of
various economic factors affecting product cost and supply. In keeping
with its established mission, the ACBSA has been asked to explore
processes and parameters which should be used in the decision-making
process for transfusion and transplantation safety policy. At the April
30 to May 1, 2009 meeting, the Committee will be asked to comment on
evidenced-based, zero-risk, cost, benefit and comparative
effectiveness, societal position or mandate, ethical, and stakeholders
concerns.
The public will have opportunity to present their views to the
Committee on both meeting days. A public comment session has been
scheduled for April 30 and May 1, 2009. Comments will be limited to
five minutes per speaker and must be pertinent to the discussion. Pre-
registration is required for participation in the public comment
session. Any
[[Page 16872]]
member of the public who would like to participate in this session is
encouraged to contact the Executive Secretary at his/her earliest
convenience. It is requested that those who wish to have printed
material distributed to the Committee provide thirty (30) copies of the
document to be distributed to the Executive Secretary, ACBSA, prior to
close of business April 27, 2009. If it is not possible to provide 30
copies of the material to be distributed, then individuals are
requested to provide at a minimum one (1) copy of the document(s) to be
distributed prior to the close of business April 27, 2009. It also is
requested that any member of the public who wishes to provide comments
to the Committee utilizing electronic data projection submit the
necessary material to the Executive Secretary prior to close of
business April 27, 2009.
Dated: April 8, 2009.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on Blood Safety and
Availability.
[FR Doc. E9-8398 Filed 4-10-09; 8:45 am]
BILLING CODE 4140-41-P
